Efficacy, tolerability and safety of once-monthly administration of 75 mg risedronate in Japanese patients with involutional osteoporosis: A comparison with a 2.5 mg once-daily dosage regimen

This report has been verified by one or more authors of the original publication.

852 Japanese patients with involutional osteoporosis were randomized to receive 75 mg oral risedronate once-monthly or 2.5 mg oral risedronate once-daily, with the purpose of comparing the efficacy, tolerability, and safety of both treatment options. Upon analysis, results indicated that 75 mg risedronate tablets taken once a month achieved similar bone mineral density and fracture rates compared to 2.5 mg risedronate tablets taken once a day. Urinary NTX/CRN and CTX/CRN bone markers decreased significantly in both groups, but resulted in a more pronounced reduction in the 2.5 mg once-daily risedronate group, while acute phase reaction adverse events were higher in the 75 mg once-monthly risedronate group.